CytRx Corporation  

(Public, NASDAQ:CYTR)   Watch this stock  
Find more results for CHERYL LOUIS´┐Ż
2.72
-0.04 (-1.45%)
Jul 31 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.70 - 2.79
52 week 2.08 - 5.42
Open 2.76
Vol / Avg. 1.84M/1.01M
Mkt cap 180.57M
P/E     -
Div/yield     -
EPS -0.94
Shares 66.39M
Beta 1.77
Inst. own 30%
Aug 4, 2015
Q2 2015 CytRx Corp Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 24, 2015
CytRx Corp Annual Shareholders Meeting (Estimated)
Jun 2, 2015
CytRx Corp at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin - -30117.98%
Operating margin - -49605.86%
EBITD margin - -49422.93%
Return on average assets -88.16% -47.36%
Return on average equity -117.46% -76.66%
Employees 26 -
CDP Score - -

Address

Suite 650, 11726 San Vicente Blvd
LOS ANGELES, CA 90049
United States - Map
+1-310-8265648 (Phone)
+1-310-8266139 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The company is focused on the clinical development of aldoxorubicin, its modified version of a chemotherapeutic agent. Aldoxorubicin is a conjugate of the commonly prescribed chemotherapeutic agent doxorubicin that binds to circulating albumin in the bloodstream and is concentrated at the site of tumors. It consists of (6-Maleimidocaproyl) hydrazine, an acid-sensitive molecule that is conjugated to doxorubicin. Its laboratory in Freiburg, Germany is conducting discovery and translational research to create drug candidates that utilize linker technologies that couple chemotherapeutic agents and proteins either inside the body or externally, and then concentrate drug in tumors.

Officers and directors

John Y Caloz Chief Financial Officer
Age: 63
Bio & Compensation  - Reuters
Daniel J Levitt M.D., Ph.D. Executive Vice President, Chief Medical Officer
Age: 67
Bio & Compensation  - Reuters
Benjamin S. Levin Senior Vice President, General Counsel, Corporate Secretary
Age: 39
Bio & Compensation  - Reuters
Douglas Scott Wieland Ph.D. Senior Vice President - Drug Development
Age: 56
Bio & Compensation  - Reuters
David J. Haen Vice President - Business Development
Age: 37
Bio & Compensation  - Reuters
Steven A. Kriegsman Chairman of the Board, President, Chief Executive Officer
Age: 73
Bio & Compensation  - Reuters
Joseph Rubinfeld Ph.D. Lead Independent Director
Age: 82
Bio & Compensation  - Reuters
Cheryl L. Cohen Director
Age: 49
Bio & Compensation  - Reuters
Anita J. Chawla Ph.D. Independent Director
Age: 56
Bio & Compensation  - Reuters
Louis J. Ignarro Ph.D. Independent Director
Age: 73
Bio & Compensation  - Reuters